history

1979 Foundation of Suntory Institute for Biomedical Research.
1980 Initiation of research work on Tetrahydrobiopterin, for treatment of genetic metabolic disease.
1981 Synthesis of α-neo-endorphin gene and production of this peptide using an E.coli expression system.
Synthesis of SUNRYTHM.
1982 Production of recombinant human IFN-γthrough application of synthetic gene.
1983 Introduction of Computer Aided Drug-design System (SCADS).
1984 Affiliation with Rockefeller University for research in central nervous system.
1985 Introduction of penem-type antibiotic FAROM through application of SCADS
1986 Establishment of production method for hANP using recombinant DNA technology.
1987 Cloning of a cDNA encoding C-terminal α-amidating enzyme.
Foundation of Suntory Institute for Medicinal Research & Development.
1988 Completion of Suntory Institute for Medicinal Research & Development.
1989 Establishment of commercially applicable production method for recombinant human calcitonin.
1990 Synthesis of penem-type antibiotic SUN A0026, a pro-drug of FAROM.
1991 Launch of SUNRYTHM, an anti-arrhythmic agent. First drug developed in-house by Suntory and the first anti-arrhythmic agent originated in Japan.
1992 Launch of BIOPTEN (sapropterin hydrochloride), for the treatment of Tetrahydrobiopterin deficiency.
Launch of BIOGAMMA, an anti-cancer agent.
1993 Establishment of commercially applicable production method for human parathyroid hormone.
1994 Synthesis of SUN N4057 for the treatment of acute stroke.
1995 Launch of HANP (human atrial natriuretic peptide) for acute heart failure.
Received Nikkei Technology Award for “Establishment of commercially applicable production method for C-terminal amidated peptide usingα-amidating enzyme.”
1997 Launch of “FAROM tablet”.
Establishment of production method for GLP-1 (anti-diabetes) using recombinant DNA technology.
Setting-up of SUNCOS, a joint venture company with ICOS in the US for the purpose of co-development of Platelet Activating Factor Acetyl Hydrolase (PAF-AH).
Acquisition of rights for development, sales and marketing of Memantine (SUN Y7017) for the treatment of dementia from Merz & Company GmbH (now Merz Pharmaceuticals)
1998 Synthesis of SUN N8075 for the treatment of acute stroke.
1999 Incorporation of Suntory Pharmaceuticals, Inc. (now Daiichi Asubio Pharmaceuticals, Inc.) for clinical development outside Japan.
Launch of the pediatrics formulation “FAROM Dry Syrup”.
Acquisition of rights for initiation of research work for the Ghrelin.
2000 Separation of the Biomedical Research Institute and its foundation as Suntory Biomedical Research Ltd., a wholly owned subsidiary of Suntory Ltd.
Incorporation of Suntory Pharmaceutical Research Laboratories in Cambridge MA, U.S.A., for discovery research.
Launch of parenteral formulation of SUNRYTHM, “SUNRYTHM Injection.”
Co-development agreement with Chugai Pharmaceutical Co., Ltd. of recombinant human parathyroid hormone (PTH) in a nasal formulation for the treatment of osteoporosis.
2002 Incorporation of Daiichi Suntory Pharma Co., Ltd.
2003 License agreement with Fujisawa Healthcare, Inc. of USA, for the development of HANP® in USA and Europe.
2004 License agreement with Replidyne, Inc. of USA for the penem-type antibiotic SUN A0026 in North America.
License agreement with BioMarin Pharmaceutical Inc.of USA for the development of BIOPTEN for the treatment of PKU.
2005 Launch of Adenoscan®
Change of the company name to Daiichi Asubio Pharma Co., Ltd and move of headquarter to Akasaka, Minato-Ku, Tokyo
2007 Change of company name to Asubio Pharma Co., Ltd. on April 1.